Drug Profile
LNP 3794
Alternative Names: BI-3011441; LNP-3794Latest Information Update: 28 Oct 2023
Price :
$50
*
At a glance
- Originator Lupin
- Developer Boehringer Ingelheim; Lupin
- Class Antineoplastics; Small molecules
- Mechanism of Action Mitogen-activated protein kinase kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Non-small cell lung cancer
- Phase I Solid tumours
Most Recent Events
- 28 Oct 2023 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Second-line therapy or greater) in Belgium (PO, Capsule)
- 28 Oct 2023 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Second-line therapy or greater) in Netherlands (PO, Capsule)
- 16 Mar 2023 Lupin completes a phase I trial in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in Belgium, Netherlands and United Kingdome (PO) (NCT05187858)